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Objective: Physical function is one of the Outcome Measures in Rheumatology (OMERACT) core outcome
domains for hand osteoarthritis studies. Our aim was to select appropriate instrument(s) to measure this
domain, as part of the development of a core outcome measurement set.
Methods: Following the OMERACT Filter 2.1 instrument selection process, the (function subscale of) the
Australian/Canadian Hand Osteoarthritis Index (AUSCAN), Functional Index for Hand Osteoarthritis
(FIHOA) and Michigan Hand Outcomes Questionnaire (MHQ) were assessed for domain match, feasibility,
truth and discrimination. Data gathered from available literature, working group and patient surveys, and
additional analyses in two hand osteoarthritis cohorts were used to inform a consensus process. Results
were summarized in Summary of Measurements Properties tables and reviewed by the OMERACT technical
advisory group.
Results: MHQ passed the assessment of domain match and feasibility by the working group and patient
research partners. For AUSCAN important limitations in feasibility were noted, but domain match was good.
FIHOA did not pass the assessment and was not taken through the follow-up assessment. Based on published
literature, reliability and construct/longitudinal validity of both MHQ and AUSCAN fulfilled OMERACT stand-
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2 F.P.B. Kroon et al. / Seminars in Arthritis and Rheumatism 00 (2021) 19Conclusion: MHQwas provisionally endorsed as OMERACT core outcome measure for the core domain physi-
cal function. While AUSCAN may have better metric properties than MHQ, it received provisional endorse-
ment as a second measure of function due to important feasibility issues. A research agenda to merit full
endorsement was set.
© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)Introduction
Physical function is an important outcome domain to evaluate in
patients with hand osteoarthritis (OA) as it is often impaired, impacts
daily living and reduces quality of life [1,2]. A variety of instruments
is available to measure hand function [3].
In 2014, the Outcome Measures in Rheumatology (OMERACT)
Hand OA Working Group endorsed a core domain set for clinical trials
of symptom and structure modification and observational studies [4].
It includes six domains for all settings (pain, physical function, patient
global assessment, health-related quality of life, joint activity, and
hand strength), and two additional domains for trials of structure
modification and observational studies (handmobility, structural dam-
age). At the same time, a preliminary core instrument set was pro-
posed, based on available literature at the time. Since then, the
Working Group worked on the development of a core outcome mea-
surement set, according to the OMERACT Filter 2.1 instrument selec-
tion process [5-7]. Preliminary work was presented and discussed at a
Special Interest Group (SIG) at OMERACT 2018 [8]. Here we report the
final instrument selection for the first OMERACT hand OA core
domain: physical function.
Material and methods
OMERACT hand OA core outcome domain set. Physical function
was the first core outcome domain for which candidate instruments
were evaluated through the OMERACT Filter 2.1 using the OMERACT
Instrument Selection Workbook templates [9]. The domain involves
self-reported limitations in physical functioning of the hands due to
OA in any of the hand joints as observed in clinical trials of symptom
or structure modification and in observational studies.
Identification and description of candidate instruments. Candidate
instruments were identified in two previously published systematic
literature reviews (SLR) of instruments measuring pain, physical
function or patient global assessment in hand OA [10,11]. Further-
more, input from the Working Group was collected at meetings at
European League Against Rheumatism (EULAR) and American College
of Rheumatology (ACR) conferences. Instruments that assess perfor-
mance-based hand function, as opposed to self-reported function,
were not considered.
Based on this, three instruments measuring physical function of
the hand were selected to be taken through the OMERACT Filter 2.1:
the Australian/Canadian Hand Osteoarthritis Index (AUSCAN) func-
tion subscale [12], the Functional Index for Hand Osteoarthritis
(FIHOA) [13] and the Michigan Hand Outcomes Questionnaire (MHQ)
overall function and activities of daily living subscales [14]. A short
description of each instrument is provided in the Appendix.
Domain match and feasibility. Domain match (including face
validity and numeric performance) and feasibility of the three instru-
ments were assessed by the working group and in a survey among
patient research partners (PRP).
Assessment of face validity and feasibility was done by the working
group, using standardized questionnaires from the OMERACT Instru-
ment Selection Workbook. Assessment of numeric performance (e.g.,
missing data patterns, floor/ceiling effects, score distribution) was
done in baseline data from the HOSTAS cohort, a Dutch observational
cohort of hand OA patients (n = 383) [15]. The assessment of domainmatch and feasibility was presented and discussed among working
groupmembers in a SIG at OMERACT 2018 [8].
Patients with hand OA (n = 48) from eight centers in different set-
tings (primary and secondary care) in seven countries worldwide
(Adelaide (Australia), Vienna (Austria), Ghent (Belgium), Leiden (The
Netherlands), Oslo (Norway), A Coru~na (Spain), Keele and Notting-
ham (United Kingdom)) were asked for their opinion on domain
match and feasibility of the instruments, using a standardized ques-
tionnaire developed by OMERACT for this purpose, and translated by
working group members to the local language if applicable. The sur-
veys were approved by the local medical ethics committees.
Based on these data, a web-based vote was held among working
group members to assess which of the instruments were suitable to
be assessed in more detail in the second part of Filter 2.1 (Fig. 1).
Colored letters represent the working group’s assessment (green
(G), good; amber (A), noncritical limitation; red (R), unsuitable). AUS-
CAN, Australian/Canadian Hand Osteoarthritis Index; FIHOA, Func-
tional Index for Hand Osteoarthritis; MHQ, Michigan Hand Outcomes
Questionnaire.
Assessment of construct validity and discrimination. Instruments
that passed the domain match and feasibility criteria were assessed for
construct validity and discrimination. For this purpose, published stud-
ies with information on construct validity, test-retest reliability, longi-
tudinal construct validity, clinical trial discrimination and thresholds
of meaning of each of the instruments in patients with hand OA were
gathered. According to OMERACT guidelines, at least two pieces of evi-
dence that support the performance of the instrument from studies
with good methods (green or amber ratings on methods) are needed
for each measurement property [7]. Where possible, we made use of
existing SLRs in the field of hand OA. In case not enough studies (at
least two) were available from the existing SLRs to assess a certain
measurement property, a complementary literature search was per-
formed to screen for additional studies. Search terms for the popula-
tion (patients with hand OA) were taken from an SLR for the EULAR
hand OA management recommendations [16]. For the measurement
properties, search terms proposed by the COSMIN group were used, as
advised in the OMERACT Instrument Selection workbook. The search
strategies can be found in the Appendix. For AUSCAN, data from a pre-
vious SLR of the OMERACT hand OA working group [10] (databases:
PubMed, Embase, Web of Science, COCHRANE, CINAHL, Academic
Search Premier, ScienceDirect; date of search from inception up to Jan-
uary 2014) and from a complementary SLR focusing on thumb base
OA [11] (databases: PubMed, EMBASE, Web of Science, COCHRANE,
CINAHL, Academic Search Premier, ScienceDirect, PEDro; date of
search from inception up to November 2010) were complemented
with a literature search for studies of thresholds of meaning (database:
PubMed; date of search: January 2014 to November 2019). For MHQ,
no SLR was available, so a literature search for all metric properties
was performed (database: PubMed; date of search: inception up to
October 2019). Clinical trials to extract data on clinical trial discrimina-
tion for both instruments were identified from a recent SLR for the
EULAR hand OA management recommendations (databases: PubMed/
MEDLINE, Embase, Cochrane CENTRAL; up to June 2017) [16].
One reviewer (FK) screened studies retrieved in the literature
searches to determine eligibility for inclusion according to predefined
inclusion criteria. Relevant data on study characteristics and the
above-mentioned measurement properties was extracted. Two
Fig. 1. The OMERACT Filter 2.1 instrument selection process for the hand OA core domain physical function.
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using the COSMINOMERACT Good Methods Checklist and sought
consensus. In case of conflict of interest through authorship a third
reviewer was consulted (IKH). Green indicates good methods (i.e.,
good avoidance of risk of bias), amber a noncritical limitation (i.e.,
some concern of risk of bias), and red unsuitable evidence (i.e., a
warning for risk of bias).
Evidence of each metric property of the instruments was
reviewed in studies with good methods (green or amber rating). We
used the OMERACT provisional standards for adequacy, outlined in
the OMERACT instrument selection workbook, to judge whether evi-
dence was supportive of adequate performance of the metric prop-
erty [7]. Evidence was rated as + (positive support), § (ambivalent
support), or  (does not reach performance standards for metric
property). Not all studies evaluating (longitudinal) construct validity
presented pre-specified hypotheses. To be able to assess whether the
study results were supportive of the instrument, the working group
compared the results to pre-specified hypotheses on (longitudinal)
construct validity from a previously published study [17].
Since only one study was identified that provided information on
thresholds of meaning of MHQ, an analysis to fill this knowledge gap
was performed by the working group. This analysis concerns unpub-
lished data. In short, we used data from a short-term clinical trial [18]
(six-week follow-up) and a long-term observational cohort study [15]
(two-year follow-up) to estimate thresholds of minimal clinically
important improvement (MCII; clinical trial) and patient acceptable
symptom state (PASS; clinical trial and observational cohort) of AUS-
CAN and MHQ in patients with hand OA. To determine these thresh-
olds, we used an anchoring method. We used a two-step anchor
question for estimation of the MCII: “Compared to when you started
the study, how has your hand function been during the last 48 h?”
(improved, no change, worse), and “If you answered improved at the
previous question, how much is this improvement?” (very much,moderately, slightly, not at all improved). We defined the MCII as the
minimal improvement in function achieved by 75% of participants
who stated to have had a slight or moderate improvement during the
trial, in line with previous studies of thresholds of meaning in OA [19].
It was calculated by taking the 75th percentile of the distribution of
AUSCAN/MHQ change scores from baseline in participants who indi-
cated to be ‘slightly’ or ‘moderately’ improved. We used the following
anchor question to estimate the PASS: “If you were to remain for the
rest of your life as you were during the last 48 h, would this be accept-
able or unacceptable for you?” (acceptable or unacceptable). The PASS
was defined as theminimal score considered acceptable for 75% of par-
ticipants, and was calculated by taking the 75th percentile of the distri-
bution of the AUSCAN/MHQ scores in participants who rated their
health ‘acceptable’. Percentiles were calculated using Stata V15.1 soft-
ware. The quality of the methods used was independently reviewed
by the OMERACT technical advisory group (TAG).
Final rating. Evidence on each metric property from studies using
good or amber methods was extracted and summarized in Summary
of Measurement Properties (SOMP) tables. Each measurement prop-
erty was given a final rating based on the gathered evidence accord-
ing to OMERACT guidance. A green rating indicates consistently good
performance from multiple studies identified as having good meth-
ods; amber indicates a noncritical limitation in the evidence, which
merits a research plan. Finally, an overall rating across all the mea-
surement properties for each instrument was proposed by the work-
ing group, evaluated by the TAG and finally brought to a broader
group of the OMERACT community for final approval of our proposed
level of endorsement.
Results
Domain match and feasibility. A comparison of the aspects of the
three instruments and the working group’s assessment of domain
Table 1
Overview of assessment of domain match and feasibility to measure physical function in hand osteoarthritis.
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and MHQ was previously published in a report of the hand OA work-
ing group SIG at OMERACT 2018 [8]. Table 1 provides an overview.
Most PRPs voted green for the three instruments (AUSCAN 79%,
FIHOA 66%, MHQ 71%) in the survey. PRP who voted amber for AUS-
CAN (21%) or MHQ (29%) suggested various additional questions to
be included, particularly more common daily tasks (AUSCAN) or
more specific questions (MHQ). While some PRP preferred FIHOA for
its brevity, MHQ was favored by others because they felt it covered
areas that AUSCAN and FIHOA did not. Generally, PRP were least posi-
tive about FIHOA (26% amber, 8% red), because they felt it missed
important questions, gender-specific questions were not appreciated
and it was felt to have items that were dated and no longer relevant
in today’s context.
In the web-based vote among the working group (n = 26; 22 clini-
cians, 19 researchers), domain match was accepted for AUSCAN (81%
green, 15% amber) and MHQ (65% green, 31% amber), but concern
was raised for FIHOA (62% amber, 12% red), mainly because voters
felt the instrument includes some outdated, culturally challenging
and gender-specific questions that are not acceptable in this day and
age. Feasibility of MHQ was accepted (46% green, 46% amber), though
important caveats are that the questionnaire is long, calculation of
the scores is not straightforward, and that it should be translated to
more languages. Feasibility of FIHOA was also accepted (81% green,
15% amber), the only concern being whether all translations are fully
validated. Feasibility of AUSCAN was problematic (58% amber, 19%
red), because the questionnaire is copyrighted and not freely avail-
able.
The concerns raised for FIHOA in its current form seriously limit
its usefulness, and would require the instrument to be modified and
subsequently revalidated. Therefore, it was decided to move forward
only the AUSCAN and MHQ through the OMERACT Filter 2.1.
Assessment of construct validity and discrimination. Fig. 2
presents a flowchart of the literature search for the detailed assess-
ment of the metric properties of AUSCAN and MHQ (PRISMA flow-
charts are additionally provided in the Appendix).For AUSCAN, the SLR by Visser et al. reported 34 studies that
applied this instrument, of which 20 studies contained relevant
quantitative data on its metric properties [10]. The SLR by Marks
et al. reported one study that applied AUSCAN [11]. The additional
search for studies on thresholds of meaning of AUSCAN yielded 2
additional inclusions. Furthermore, one additional clinical trial was
identified in the SLR by Kroon et al. [16]. In total, 24 studies provided
evidence for construct validity (n = 9) [12,20-27], test-retest reliabil-
ity (n = 4) [12,21,23,28], longitudinal construct validity (n = 5) [22,29-
32], clinical trial discrimination (n = 8) [12,18,33-38], and thresholds
of meaning (n = 3) [19,39,40]. Most studies on (longitudinal) con-
struct validity had amber methods, because the authors had not
clearly pre-specified their hypotheses. Data from two studies could
not be used based on the good methods check: one construct validity
study was unsuitable because it used AUSCAN as the external stan-
dard [22], and one test-retest reliability study used unsuitable analy-
sis methods [28]. Clinical trials that were judged amber had no
control group [37], were not blinded [35,38] or had no expected
change in the intervention group [34]. Two studies on thresholds of
meaning had low risk of bias [19,40], and one had amber methods
[39]. Generally, studies supported adequate performance of the mea-
surement properties of the AUSCAN.
For MHQ, our literature search yielded 5 studies which met inclu-
sion criteria, and 3 additional clinical trials were identified (Fig. 2). In
total, 8 studies provided evidence for construct validity (n = 4)
[17,41-43], test-retest reliability (n = 2) [42,44], longitudinal con-
struct validity (n = 3) [17,42,43], clinical trial discrimination (n = 3)
[18,45,46], and thresholds of meaning (n = 1) [42]. Three studies on
(longitudinal) construct validity had amber methods, because they
lacked pre-specified hypotheses. One construct validity study was
unsuitable because MHQ was used as the external standard [43]. One
clinical trial had amber methods because it was an open study [46].
Test-retest reliability and threshold of meaning studies had low risk
of bias. Though less studies were available compared to AUSCAN,
overall, evidence supported adequate performance of the measure-
ment properties of the MHQ. Only for clinical trial discrimination
Fig. 2. Flowchart of studies for assessment of construct validity and discrimination of AUSCAN (upper) and MHQ (lower).
ARTICLE IN PRESS
F.P.B. Kroon et al. / Seminars in Arthritis and Rheumatism 00 (2021) 19 5evidence was inconsistent, with two studies being supportive (green
[45] and amber methods [46]) while in a third study (green methods
[18]) MHQ was less sensitive than other function instruments to
measure clinical response to treatment.
*8 trials were also identified through the SLR by Visser et al. and
therefore excluded as duplicates. AUSCAN, Australian/Canadian Hand
Osteoarthritis Index; CTD, clinical trial discrimination; CV, construct
validity; LCV, longitudinal construct validity; MHQ, Michigan Hand
Outcomes Questionnaire; SLR, systematic literature review, TM,
thresholds of meaning; TRT, test-retest reliability.
Only one published study was available to provide evidence on
thresholds of meaning of the MHQ. Therefore, we conducted a sepa-
rate analysis to estimate MCII and PASS of both instruments. While
AUSCAN had a credible MCII (e.g., relative percentage improvementof 9.8%), comparable to previous literature, the MCII estimates of
MHQ were small values in the wrong direction of effect, which would
indicate that even a small worsening was rated as a functional
improvement. PASS values lie around 50% of the possible maximum
score for AUSCAN and MHQ overall hand function, while for MHQ
ADL a relatively high PASS was indicative of a floor effect. All in all,
these results seem more supportive of AUSCAN than MHQ when it
comes to measurement of improvement in a clinical trial setting, in
line with the results for clinical trial discrimination that we found in
the literature.
Final rating. Fig. 3 presents the SOMP table of AUSCAN (A) and
MHQ (B). The combined rating of the evidence was supportive of a
provisional endorsement of both MHQ subscales as core outcome
measurement instrument (Fig. 3B). The working group noted the
Fig. 3. OMERACT Summary of Measurement Properties (SOMP) tables of AUSCAN (function subscale) (A) and MHQ (overall functiona and activities of daily livingb subscales) (B). The color
represents the good methods assessment (green, good; amber, noncritical limitation; red, unsuitable evidence). The sign represents the adequacy of the data in support of the instrument
(+, positive support; §, ambivalent support; , does not reach performance standards for metric property). For MHQ, superscript letters denote whether the evidence in that cell pertains
to the overall functiona or the activities of daily livingb subscale. AUSCAN, Australian/Canadian Hand Osteoarthritis Index; MHQ,Michigan Hand Outcomes Questionnaire.
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on their research agenda. AUSCAN received a provisional endorse-
ment to serve as a second measure of function (Fig. 3A). While AUS-
CAN function may have better metric properties than MHQ, the
working group felt that due to important feasibility issues (i.e., not
available in public domain, costs associated with use of question-
naire), this instrument could not be recommended as a mandatory
instrument to measure function in all hand OA trials.
Discussion
We evaluated appropriate instruments to measure the domain
physical function in hand OA, as part of the development of an
OMERACT core outcome measurement set. We identified the MHQ
and AUSCAN as the first patient-reported instruments provisionally
endorsed as core outcome measurement instruments for hand OA
clinical trials, based on the OMERACT Filter 2.1 process.
Whilst at the moment the AUSCAN is more commonly used to
measure physical function in hand OA studies, this instrument has
important limitations in feasibility, i.e. the questionnaire is copy-
righted and may only be used with permission and after payment of
a considerable fee. This led to the decision to not recommend AUS-
CAN as a primary measure of function. Such limitations in feasibility
were not present for MHQ. However, particularly evidence for clinical
trial discrimination and thresholds of meaning was inconsistent, and
further research is therefore warranted. Full endorsement of the
MHQ as the core outcome measurement instrument for physical
function depends on the results of future studies into the remaining
amber metric properties (longitudinal construct validity, clinical trial
discrimination and thresholds of meaning). It would require support-
ive evidence (“+”) for these metric properties provided by studies
with good methods or a low risk of bias (“green”). Full endorsement
of AUSCAN is not possible in its current form given the identified lim-
itations in terms of feasibility.
Whilst the FIHOA was proposed as a candidate instrument in the
preliminary core instrument set [4], it was rejected as a core outcome
measure for hand OA trials, after careful assessment of domain match
and feasibility.
Notably, many of the studies on (longitudinal) construct validity
for AUSCAN and MHQ were rated as having amber methods due to
lack of (reporting of) pre-specified hypotheses, yet the results of the
studies were generally supportive of the measurement property.
Reporting standards for future studies of measurement properties of
instruments could be useful to improve this.
The working group also aims to publish the additional analyses on
thresholds of meaning in a peer-reviewed journal.
Our study is not the first to review and appraise different mea-
surement instruments of hand function for patients with hand OA. In
2005, Dziedzic et al. published a narrative review describing and crit-
ically appraising five instruments used to measure disability in
patients with hand OA, including the AUSCAN and FIHOA [47]. While
they also used the OMERACT constructs of truth, discrimination and
feasibility, their work differs from ours in several aspects. They did
not focus on instruments measuring physical function of the hand
specifically (i.e., the core domain for which we wanted to select a
suitable measurement instrument), but also assessed instruments
that measure ‘disability’ in a broader sense, such as the Health
Assessment Questionnaire. Besides, their objective was to identify
and appraise instruments for a specific application (general popula-
tion surveys in primary care setting), while our work expands to
instruments suitable for studies in all settings. Moreover, their search
was performed until 2002, they used the old OMERACT framework
(Filter 1.0), did not critically appraise the quality of the studies pro-
viding data on the measurement properties of instruments, and no
voting in the OMERACT community was done or level of endorse-
ment presented. A recent narrative review by van de Stadt et al.provides an overview of all available instruments to measure hand
function, including an overview of evidence for their measurement
properties, without focusing on hand osteoarthritis specifically [3].
Physical function is the first core domain from the OMERACT hand
OA core outcome set for which core outcome measurement instru-
ments have been endorsed. The working group will proceed with the
assessment of instruments for the other core domains, with the ulti-
mate goal of developing a complete hand OA core outcome measure-
ment set.
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